Alteogen Charges 17 Billion KRW Technology Fee to Partner Entering Phase 3 Clinical Trial
Alteogen, a biopharmaceutical development company, announced on the 3rd that it has invoiced its partner company for a milestone payment (royalty) of $13 million (approximately 17 billion KRW) following the entry of the first application item of Hybrozyme into Phase 3 clinical trials.
Hot Picks Today
!["Stock Set to Double: This Company Smiles Every Time a Data Center Is Built [Click e-Stock]"](https://cwcontent.asiae.co.kr/asiaresize/93/2026050416112750184_1777878687.jpg)
"Stock Set to Double: This Company Smiles Every...
- "Continuous Groundwater Extraction Causes Mexico City of 22 Million to Sink by 2...
- "Is Yours Just Gathering Dust at Home? Millennials & Gen Z Rediscover Digicams O...
- "Going to Seongsu-dong?" Japanese Girl Group Faces Taxi Refusal in Seoul
- "Prime Minister in Underwear?"... Italy's Meloni Posts Herself to Warn of Deepfa...
Hybrozyme is a subcutaneous (SC) formulation change platform that uses Alteogen's recombinant hyaluronidase 'ALT-B4'. This announcement follows the Phase 3 clinical trial entry of the partner company to which the technology was licensed in 2020. The invoiced payment is typically received within one month.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
